U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H19NO
Molecular Weight 241.3288
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LITOXETINE

SMILES

c1ccc2cc(ccc2c1)COC3CCNCC3

InChI

InChIKey=MJJDYOLPMGIWND-UHFFFAOYSA-N
InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2

HIDE SMILES / InChI

Molecular Formula C16H19NO
Molecular Weight 241.3288
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Litoxetine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and mixed serotonin agonist-antagonist, which makes it particularly appropriate for treating continence dysfunctions. Litoxetine at concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxations in the rat isolated oesophageal muscularis mucosae, which reduced carbachol tone up to 37%. Higher litoxetine concentrations (3 microM-300 microM) were associated with marked relaxation up to the abolition of carbachol tone. The antimuscarinic activity of litoxetine, previously demonstrated in the isolated guinea-pig intestine, played a role in the rat isolated oesophageal muscularis mucosae at concentrations greater than 1 microM. The 5-HT-releasing action of litoxetine could account for the potentation by litoxetine of 5-HT-induced relaxation in tissues from untreated rats, which was reversed by pCPA treatment. Litoxetine is in phase II clinical trial for the treatment of urinary incontinence.

Approval Year

PubMed

PubMed

TitleDatePubMed
Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro.
1988
A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
1989 Nov 1
Advances in sodium-ion coupled biogenic amine transporters.
1992
Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice.
1992 May
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties.
1993 Mar 2
EEG profile of litoxetine after single and repeated administration in healthy volunteers.
1994 Feb
The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors.
1995 Mar
Influence of fluoxetine and litoxetine on 5-HT4 receptor-mediated relaxation in the rat isolated oesophagus.
1999
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
2002 Apr
Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.
2009 Apr 15
Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
2009 Oct 15

Sample Use Guides

2.5 mg, 5 mg, 10 mg, 25 mg or placebo twice daily on days 1-4 and once on day 5
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:10:40 UTC 2021
Edited
by admin
on Sat Jun 26 08:10:40 UTC 2021
Record UNII
9980ST005G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LITOXETINE
INN  
INN  
Official Name English
4-(2-NAPHTHYLMETHOXY)PIPERIDINE
Systematic Name English
LITOXETINE [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
Code System Code Type Description
INN
6662
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
EVMPD
SUB08536MIG
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
CAS
86811-09-8
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
FDA UNII
9980ST005G
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
ChEMBL
CHEMBL471036
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
WIKIPEDIA
Litoxetine
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
NCI_THESAURUS
C66021
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
MESH
C057048
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
DRUG BANK
DB15038
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
EPA CompTox
86811-09-8
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
PUBCHEM
65650
Created by admin on Sat Jun 26 08:10:40 UTC 2021 , Edited by admin on Sat Jun 26 08:10:40 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY